Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TOP2A | P11388 | 1/20 | 0.41 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9168089 | 0.80 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3CYP19A1MAPT | |
| SCHEMBL31143614 | 0.80 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3MAPTSMN1; SMN2 | |
| SCHEMBL31143646 | 0.80 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3MAPTSMN1; SMN2 | |
| SCHEMBL23610057 | 0.80 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3MAPTSMN1; SMN2 | |
| SCHEMBL477369 | 0.80 | SLC6A2 (0.63) | SLC6A2SLC6A4SLC6A3MAPTSMN1; SMN2 | |
| SCHEMBL15709920 | 0.79 | AHR (0.54) | SLC6A2SLC6A4SLC6A3CYP19A1MAPT | |
| SCHEMBL23882793 | 0.79 | CYP19A1 (0.44) | CYP19A1TOP2ATOP2BKMT2AGAA | |
| SCHEMBL23610045 | 0.77 | SLC6A3 (0.46) | SLC6A2SLC6A4SLC6A3MAPTKMT2A | |
| SCHEMBL23610040 | 0.77 | BRD4 (0.49) | SLC6A2SLC6A4SLC6A3MAPTKMT2A | |
| SCHEMBL21246926 | 0.77 | SLC6A2 (0.51) | SLC6A2SLC6A4SLC6A3MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126835-B1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12516038-B2 | Inhibitors of antigen presentation by HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-06 | — | — | US | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| EP-4126835-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021198283-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-07 | — | — | WO | disclosed |
| WO-2016016421-A1 | 2-AMINO-BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS 5-LIPOXYGENASE AND/OR PROSTAGLANDIN E SYNTHASE INHIBITORS | INSTITUT PASTEUR KOREA (KR) | 2016-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | SLC6A2 3684/4885SLC6A4 3307/4885SLC6A3 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.